Increase in the number of diabetic patients is the factor basically driving the gastroparesis treatment market. Gastroparesis treatment regularizes the digestive process that was disturbed with the onset of constipation or irritable bowel syndrome, or any other disease, followed by diabetes.
Many drugs are in pipeline, which is an outcome of the companies and research institutes being funded by government and non-government agencies.
The key players in gastroparesis treatment market are investing noticeably in the new product launch. They are thus expediting the development of new drugs for gastroparesis so that approvals can be sought from the regulatory bodies such as the U.S. FDA for the betterment of the end-users.
Gastroparesis treatment market adversely affects movement of muscles in the abdomen. It can interfere with usual digestion and result in nausea, stomachache, and vomiting sensation.
The drug candidates that are developed as well as investigated for treating gastroparesis have depicted promising results in the clinical trials. As an outcome, the regulatory authorities such as the U.S. FDA are going for speedy approvals of these candidates.
Additionally, the Institute for Health Metrics and Evaluation (IHME) has reported increase in diabetes cases globally. In other words, as per the IHME, the number of diabetes cases is expected to increase from 529 million to 1.3 billion by the year 2050. As of now, diabetes is one of the 10 leading causes of disability and fatality. Severity on the part of diabetes may also result in diabetic gastroparesis.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Diabetic gastroparesis means a potential complication that occurs when diabetes is improperly controlled. This actually results out of dysfunction in functioning and co-ordination of automatic nervous system, specialized pacemaker cells (interstitial cells of Cajal, ICC), and neurons.
The vaugus nerve gets damaged after a while of poor glucose control, thereby resulting in gastroparesis. The early symptoms of gastroparesis include nausea, early fullness, weight loss, and vomiting.
As per Diabetes Atlas, 537 million adults worldwide are suffering from diabetes in the present scenario. It further states that this number is expected to increase to 643 million by the year 2030 and 783 million by the year 2045.
As of now, metoclopramide, a prokinetic, is the only FDA-approved medication for treating gastroparesis. It is prescribed as the first-line treatment with respect to gastroparesis.
Continual research carried out regarding gastroparesis treatment is thus stimulating the gastroparesis treatment industry growth.
Continual research is being conducted to bring new drugs to treat gastroparesis. In May 2024, Deudomperidone entered the Phase II trial in adults suffering from diabetic gastroparesis.
CinDome Pharma, who has launched this drug, has obtained US$ 40 Mn as a part of a Series B financing extension round that is aimed at advancing development of Deudomperidone (CIN-102) as one of the potential treatments for chronic gastroparesis.
As per studies presented at the 2023 Annual Meeting of the American College of gastroenterology, gastric peroral endoscopic myotomy is likely to help patients suffering from persistent gastroparesis.
In September 2023, Aclipse Therapeutics, along with its subsidiary called Aclipse Two, Inc., announced that it had inked a special license agreement with Chong Kun Dang Pharmaceutical Corporation (CKD) for worldwide rights, so as to develop the latter’s lobeglitazone for gastroparesis and several other conditions.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest gastroparesis treatment market analysis, North America held the largest share of gastroparesis remedies landscape in 2023 and the scenario is expected to remain unchanged during the forecast period.
This is attributed to the U.S. being home to a huge pre-diabetic population coupled with conducive reimbursement policies. As per the data released by CDC in June 2022, 96 million adults were living with prediabetes, which constituted 38% of the adult population of the U.S.
Furthermore, as per the Immune Deficiency Foundation (IDF), nearly 51 million people were battling diabetes in Caribbean and North America in 2021. IT further states that the number is expected to increase to 57 million by the year 2030, and 63 million by 2045.
As per Diabetes Canada in February 2022, 5,719,000 individuals were to be diagnosed with diabetes in 2022 and the number would reach 7,277,000 by the year 2032.
The key participants in gastroparesis treatment market are involved in conducting clinical trials to sustain themselves in the gastroparesis therapy landscape.
For instance, in February 2022, Vanda Pharmaceuticals Inc. (Vanda) shared outcomes of the Phase III clinical trial called VP-VLY-686-3303, which revealed safety and effectiveness of tradipitant in addressing symptoms of gastroparesis.
Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bayer AG, Cipla Limited, Evoke Pharma, Pfizer Inc., Salix Pharmaceuticals, Inc., The Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. are some of the key players covered in the gastroparesis treatment market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 6.3 Bn |
| Market Forecast (Value) in 2034 | US$ 10.3 Bn |
| Growth Rate (CAGR) | 4.6% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 6.3 Bn in 2023
It is projected to grow at a CAGR of 4.6% from 2024 to 2034
Growing prevalence of diabetes and continuous influx of new drugs
Retail pharmacies segment accounted for the largest share in 2023
North America was the dominant region in 2023
Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bayer AG, Cipla Limited, Evoke Pharma, Pfizer Inc., Salix Pharmaceuticals, Inc., The Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Gastroparesis Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gastroparesis Treatment Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Gastroparesis Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. Prokinetic Agents
6.3.2. Antiemetic Drugs
6.3.3. Proton Pump Inhibitors
6.3.4. Others (Botulinum Toxin Injections, etc.)
6.4. Market Attractiveness, by Drug Class
7. Global Gastroparesis Treatment Market Analysis and Forecast, by Disease Indication
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Indication, 2020-2034
7.3.1. Diabetes Gastroparesis
7.3.2. Idiopathic Gastroparesis
7.3.3. Post-surgical Gastroparesis
7.4. Market Attractiveness, by Disease Indication
8. Global Gastroparesis Treatment Market Analysis and Forecast, By Type
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, By Type, 2020-2034
8.3.1. Over-the-Counter Drugs
8.3.2. Prescription Drugs
8.4. Market Attractiveness, By Type
9. Global Gastroparesis Treatment Market Analysis and Forecast, by Route of Administration
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Route of Administration, 2020-2034
9.3.1. Oral
9.3.2. Injectables
9.3.3. Nasal
9.4. Market Attractiveness, by Route of Administration
10. Global Gastroparesis Treatment Market Analysis and Forecast, by Distribution Channel
10.1. Introduction and Definitions
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Distribution Channel, 2020-2034
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Attractiveness, by Distribution Channel
11. Global Gastroparesis Treatment Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2020-2034
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness, by Region
12. North America Gastroparesis Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2020-2034
12.2.1. Prokinetic Agents
12.2.2. Antiemetic Drugs
12.2.3. Proton Pump Inhibitors
12.2.4. Others (Botulinum Toxin Injections, etc.)
12.3. Market Attractiveness, by Drug Class
12.4. Market Value Forecast, by Disease Indication, 2020-2034
12.4.1. Diabetes Gastroparesis
12.4.2. Idiopathic Gastroparesis
12.4.3. Post-surgical Gastroparesis
12.5. Market Attractiveness, by Disease Indication
12.6. Market Value Forecast, By Type, 2020-2034
12.6.1. Over-the-Counter Drugs
12.6.2. Prescription Drugs
12.7. Market Attractiveness, By Type
12.8. Market Value Forecast, by Route of Administration, 2020-2034
12.8.1. Oral
12.8.2. Injectables
12.8.3. Nasal
12.9. Market Attractiveness, by Route of Administration
12.10. Market Value Forecast, by Distribution Channel, 2020-2034
12.10.1. Hospital Pharmacies
12.10.2. Retail Pharmacies
12.10.3. Online Pharmacies
12.11. Market Attractiveness, by Distribution Channel
12.12. Market Value Forecast, by Country/Sub-region, 2020-2034
12.12.1. U.S.
12.12.2. Canada
12.13. Market Attractiveness Analysis
12.13.1. By Drug Class
12.13.2. By Disease Indication
12.13.3. By Type
12.13.4. By Route of Administration
12.13.5. By Distribution Channel
12.13.6. By Country
13. Europe Gastroparesis Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2020-2034
13.2.1. Prokinetic Agents
13.2.2. Antiemetic Drugs
13.2.3. Proton Pump Inhibitors
13.2.4. Others (Botulinum Toxin Injections, etc.)
13.3. Market Attractiveness, by Drug Class
13.4. Market Value Forecast, by Disease Indication, 2020-2034
13.4.1. Diabetes Gastroparesis
13.4.2. Idiopathic Gastroparesis
13.4.3. Post-surgical Gastroparesis
13.5. Market Attractiveness, by Disease Indication
13.6. Market Value Forecast, By Type, 2020-2034
13.6.1. Over-the-Counter Drugs
13.6.2. Prescription Drugs
13.7. Market Attractiveness, By Type
13.8. Market Value Forecast, by Route of Administration, 2020-2034
13.8.1. Oral
13.8.2. Injectables
13.8.3. Nasal
13.9. Market Attractiveness, by Route of Administration
13.10. Market Value Forecast, by Distribution Channel, 2020-2034
13.10.1. Hospital Pharmacies
13.10.2. Retail Pharmacies
13.10.3. Online Pharmacies
13.11. Market Attractiveness, by Distribution Channel
13.12. Market Value Forecast, by Country/Sub-region, 2020-2034
13.12.1. Germany
13.12.2. U.K.
13.12.3. France
13.12.4. Italy
13.12.5. Spain
13.12.6. Rest of Europe
13.13. Market Attractiveness Analysis
13.13.1. By Drug Class
13.13.2. By Disease Indication
13.13.3. By Type
13.13.4. By Route of Administration
13.13.5. By Distribution Channel
13.13.6. By Country/Sub-region
14. Asia Pacific Gastroparesis Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2020-2034
14.2.1. Prokinetic Agents
14.2.2. Antiemetic Drugs
14.2.3. Proton Pump Inhibitors
14.2.4. Others (Botulinum Toxin Injections, etc.)
14.3. Market Attractiveness, by Drug Class
14.4. Market Value Forecast, by Disease Indication, 2020-2034
14.4.1. Diabetes Gastroparesis
14.4.2. Idiopathic Gastroparesis
14.4.3. Post-surgical Gastroparesis
14.5. Market Attractiveness, by Disease Indication
14.6. Market Value Forecast, By Type, 2020-2034
14.6.1. Over-the-Counter Drugs
14.6.2. Prescription Drugs
14.7. Market Attractiveness, By Type
14.8. Market Value Forecast, by Route of Administration, 2020-2034
14.8.1. Oral
14.8.2. Injectables
14.8.3. Nasal
14.9. Market Attractiveness, by Route of Administration
14.10. Market Value Forecast, by Distribution Channel, 2020-2034
14.10.1. Hospital Pharmacies
14.10.2. Retail Pharmacies
14.10.3. Online Pharmacies
14.11. Market Attractiveness, by Distribution Channel
14.12. Market Value Forecast, by Country/Sub-region, 2020-2034
14.12.1. China
14.12.2. Japan
14.12.3. India
14.12.4. Australia & New Zealand
14.12.5. Rest of Asia Pacific
14.13. Market Attractiveness Analysis
14.13.1. By Drug Class
14.13.2. By Disease Indication
14.13.3. By Type
14.13.4. By Route of Administration
14.13.5. By Distribution Channel
14.13.6. By Country/Sub-region
15. Latin America Gastroparesis Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2020-2034
15.2.1. Prokinetic Agents
15.2.2. Antiemetic Drugs
15.2.3. Proton Pump Inhibitors
15.2.4. Others (Botulinum Toxin Injections, etc.)
15.3. Market Attractiveness, by Drug Class
15.4. Market Value Forecast, by Disease Indication, 2020-2034
15.4.1. Diabetes Gastroparesis
15.4.2. Idiopathic Gastroparesis
15.4.3. Post-surgical Gastroparesis
15.5. Market Attractiveness, by Disease Indication
15.6. Market Value Forecast, By Type, 2020-2034
15.6.1. Over-the-Counter Drugs
15.6.2. Prescription Drugs
15.7. Market Attractiveness, By Type
15.8. Market Value Forecast, by Route of Administration, 2020-2034
15.8.1. Oral
15.8.2. Injectables
15.8.3. Nasal
15.9. Market Attractiveness, by Route of Administration
15.10. Market Value Forecast, by Distribution Channel, 2020-2034
15.10.1. Hospital Pharmacies
15.10.2. Retail Pharmacies
15.10.3. Online Pharmacies
15.11. Market Attractiveness, by Distribution Channel
15.12. Market Value Forecast, by Country/Sub-region, 2020-2034
15.12.1. Brazil
15.12.2. Mexico
15.12.3. Rest of Latin America
15.13. Market Attractiveness Analysis
15.13.1. By Drug Class
15.13.2. By Disease Indication
15.13.3. By Type
15.13.4. By Route of Administration
15.13.5. By Distribution Channel
15.13.6. By Country/Sub-region
16. Middle East & Africa Gastroparesis Treatment Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Drug Class, 2020-2034
16.2.1. Prokinetic Agents
16.2.2. Antiemetic Drugs
16.2.3. Proton Pump Inhibitors
16.2.4. Others (Botulinum Toxin Injections, etc.)
16.3. Market Attractiveness, by Drug Class
16.4. Market Value Forecast, by Disease Indication, 2020-2034
16.4.1. Diabetes Gastroparesis
16.4.2. Idiopathic Gastroparesis
16.4.3. Post-surgical Gastroparesis
16.5. Market Attractiveness, by Disease Indication
16.6. Market Value Forecast, By Type, 2020-2034
16.6.1. Over-the-Counter Drugs
16.6.2. Prescription Drugs
16.7. Market Attractiveness, By Type
16.8. Market Value Forecast, by Route of Administration, 2020-2034
16.8.1. Oral
16.8.2. Injectables
16.8.3. Nasal
16.9. Market Attractiveness, by Route of Administration
16.10. Market Value Forecast, by Distribution Channel, 2020-2034
16.10.1. Hospital Pharmacies
16.10.2. Retail Pharmacies
16.10.3. Online Pharmacies
16.11. Market Attractiveness, by Distribution Channel
16.12. Market Value Forecast, by Country/Sub-region, 2020-2034
16.12.1. GCC Countries
16.12.2. South Africa
16.12.3. Rest of Middle East & Africa
16.13. Market Attractiveness Analysis
16.13.1. By Drug Class
16.13.2. By Disease Indication
16.13.3. By Type
16.13.4. By Route of Administration
16.13.5. By Distribution Channel
16.13.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix (By Tier and Size of Companies)
17.2. Market Share Analysis, by Company (2023)
17.3. Company Profiles
17.3.1. Abbott Laboratories
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. AbbVie Inc.
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. AstraZeneca plc
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. Bayer AG
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. Cipla Limited
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. Evoke Pharma
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. Pfizer Inc.
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. Salix Pharmaceuticals, Inc.
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. The Takeda Pharmaceutical Company Limited
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
17.3.10. Teva Pharmaceutical Industries Ltd.
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. Financial Overview
17.3.10.4. SWOT Analysis
17.3.10.5. Strategic Overview
List of Tables
Table 01: Global Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 02: Global Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 03: Global Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 04: Global Gastroparesis Treatment Market Size (US$ Bn) Forecast, By Type, 2020-2034
Table 05: Global Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 06: Global Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 07: North America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 08: North America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 09: North America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 10: North America Gastroparesis Treatment Market Size (US$ Bn) Forecast, By Type, 2020-2034
Table 11: North America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 12: North America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 13: Europe Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Europe Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 15: Europe Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 16: Europe Gastroparesis Treatment Market Size (US$ Bn) Forecast, By Type, 2020-2034
Table 17: Europe Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 18: Europe Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 19: Asia Pacific Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 20: Asia Pacific Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 21: Asia Pacific Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 22: Asia Pacific Gastroparesis Treatment Market Size (US$ Bn) Forecast, By Type, 2020-2034
Table 23: Asia Pacific Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 24: Asia Pacific Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 25: Latin America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 26: Latin America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 27: Latin America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 28: Latin America Gastroparesis Treatment Market Size (US$ Bn) Forecast, By Type, 2020-2034
Table 29: Latin America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 30: Latin America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 31: Middle East & Africa Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 32: Middle East & Africa Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 33: Middle East & Africa Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 34: Middle East & Africa Gastroparesis Treatment Market Size (US$ Bn) Forecast, By Type, 2020-2034
Table 35: Middle East & Africa Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 36: Middle East & Africa Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
List of Figures
Figure 01: Global Gastroparesis Treatment Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Gastroparesis Treatment Market Revenue (US$ Bn), by Drug Class, 2023
Figure 03: Global Gastroparesis Treatment Market Value Share, by Drug Class, 2023
Figure 04: Global Gastroparesis Treatment Market Revenue (US$ Bn), by Disease Indication, 2023
Figure 05: Global Gastroparesis Treatment Market Value Share, by Disease Indication, 2023
Figure 06: Global Gastroparesis Treatment Market Revenue (US$ Bn), By Type, 2023
Figure 07: Global Gastroparesis Treatment Market Value Share, By Type, 2023
Figure 08: Global Gastroparesis Treatment Market Revenue (US$ Bn), by Route of Administration, 2023
Figure 09: Global Gastroparesis Treatment Market Value Share, by Route of Administration, 2023
Figure 10: Global Gastroparesis Treatment Market Revenue (US$ Bn), by Distribution Channel, 2023
Figure 11: Global Gastroparesis Treatment Market Value Share, by Distribution Channel, 2023
Figure 12: Global Gastroparesis Treatment Market Value Share, by Region, 2023
Figure 13: Global Gastroparesis Treatment Market Value (US$ Bn) Forecast, 2020-2034
Figure 14: Global Gastroparesis Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 15: Global Gastroparesis Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 16: Global Gastroparesis Treatment Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 17: Global Gastroparesis Treatment Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 18: Global Gastroparesis Treatment Market Value Share Analysis, By Type, 2023 and 2034
Figure 19: Global Gastroparesis Treatment Market Attractiveness Analysis, By Type, 2024-2034
Figure 20: Global Gastroparesis Treatment Market Revenue (US$ Bn), by Route of Administration, 2023
Figure 21: Global Gastroparesis Treatment Market Value Share, by Route of Administration, 2023
Figure 22: Global Gastroparesis Treatment Market Revenue (US$ Bn), by Distribution Channel, 2023
Figure 23: Global Gastroparesis Treatment Market Value Share, by Distribution Channel, 2023
Figure 24: Global Gastroparesis Treatment Market Value Share Analysis, by Region, 2023 and 2034
Figure 25: Global Gastroparesis Treatment Market Attractiveness Analysis, by Region, 2024-2034
Figure 26: North America Gastroparesis Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 27: North America Gastroparesis Treatment Market Attractiveness Analysis, by Country, 2024-2034
Figure 28: North America Gastroparesis Treatment Market Value Share Analysis, by Country, 2023 and 2034
Figure 29: North America Gastroparesis Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 30: North America Gastroparesis Treatment Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 31: North America Gastroparesis Treatment Market Value Share Analysis, By Type, 2023 and 2034
Figure 32: North America Gastroparesis Treatment Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 33: North America Gastroparesis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 34: North America Gastroparesis Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 35: North America Gastroparesis Treatment Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 36: North America Gastroparesis Treatment Market Attractiveness Analysis, By Type, 2023-2034
Figure 37: North America Gastroparesis Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 38: North America Gastroparesis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 39: Europe Gastroparesis Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 40: Europe Gastroparesis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 41: Europe Gastroparesis Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 42: Europe Gastroparesis Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 43: Europe Gastroparesis Treatment Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 44: Europe Gastroparesis Treatment Market Value Share Analysis, By Type, 2023 and 2034
Figure 45: Europe Gastroparesis Treatment Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 46: Europe Gastroparesis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 47: Europe Gastroparesis Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 48: Europe Gastroparesis Treatment Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 49: Europe Gastroparesis Treatment Market Attractiveness Analysis, By Type, 2024-2034
Figure 50: Europe Gastroparesis Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 51: Europe Gastroparesis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 52: Asia Pacific Gastroparesis Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 53: Asia Pacific Gastroparesis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 54: Asia Pacific Gastroparesis Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 55: Asia Pacific Gastroparesis Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 56: Asia Pacific Gastroparesis Treatment Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 57: Asia Pacific Gastroparesis Treatment Market Value Share Analysis, By Type, 2023 and 2034
Figure 58: Asia Pacific Gastroparesis Treatment Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 59: Asia Pacific Gastroparesis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 60: Asia Pacific Gastroparesis Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 61: Asia Pacific Gastroparesis Treatment Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 62: Asia Pacific Gastroparesis Treatment Market Attractiveness Analysis, By Type, 2024-2034
Figure 63: Asia Pacific Gastroparesis Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 64: Asia Pacific Gastroparesis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 65: Latin America Gastroparesis Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 66: Latin America Gastroparesis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 67: Latin America Gastroparesis Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 68: Latin America Gastroparesis Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 69: Latin America Gastroparesis Treatment Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 70: Latin America Gastroparesis Treatment Market Value Share Analysis, By Type, 2023 and 2034
Figure 71: Latin America Gastroparesis Treatment Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 72: Latin America Gastroparesis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 73: Latin America Gastroparesis Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 74: Latin America Gastroparesis Treatment Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 75: Latin America Gastroparesis Treatment Market Attractiveness Analysis, By Type, 2023-2034
Figure 76: Latin America Gastroparesis Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 77: Latin America Gastroparesis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 78: Middle East & Africa Gastroparesis Treatment Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 79: Middle East & Africa Gastroparesis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 80: Middle East & Africa Gastroparesis Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 81: Middle East & Africa Gastroparesis Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 82: Middle East & Africa Gastroparesis Treatment Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 83: Middle East & Africa Gastroparesis Treatment Market Value Share Analysis, By Type, 2023 and 2034
Figure 84: Middle East & Africa Gastroparesis Treatment Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 85: Middle East & Africa Gastroparesis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 86: Middle East & Africa Gastroparesis Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 87: Middle East & Africa Gastroparesis Treatment Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 88: Middle East & Africa Gastroparesis Treatment Market Attractiveness Analysis, By Type, 2023-2034
Figure 89: Middle East & Africa Gastroparesis Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 90: Middle East & Africa Gastroparesis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Gastroparesis Treatment Market
